No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk-An analysis of Finnish health register and German health insurance data

Epilepsia ◽  
2018 ◽  
Vol 59 (7) ◽  
pp. 1303-1306 ◽  
Author(s):  
Christoph Helmstaedter ◽  
Ettore Beghi ◽  
Christian E. Elger ◽  
Reetta Kälviäinen ◽  
Kristina Malmgren ◽  
...  
Keyword(s):  
Health Insurance ◽  
Drug Treatment ◽  
Antiepileptic Drug ◽  
Causal Relationship ◽  
Antiepileptic Drugs ◽  
Health Insurance Data ◽  
German Health ◽  
Dementia Risk ◽  
Antiepileptic Drug Treatment ◽  
Insurance Data

scholarly journals Reply to: Use of Antiepileptic Drugs and Dementia Risk-an Analysis of Finnish Health Register and German Health Insurance Data

2018 ◽  
Vol 66 (9) ◽  
pp. 1853-1854
Author(s):  
Heidi Taipale ◽  
Willy Gomm ◽  
Karl Broich ◽  
Wolfgang Maier ◽  
Anna-Maija Tolppanen ◽  
...  
Keyword(s):  
Health Insurance ◽  
Antiepileptic Drugs ◽  
Health Insurance Data ◽  
German Health ◽  
Dementia Risk ◽  
Insurance Data

Use of Antiepileptic Drugs and Dementia Risk-an Analysis of Finnish Health Register and German Health Insurance Data

2018 ◽  
Vol 66 (6) ◽  
pp. 1123-1129 ◽  
Author(s):  
Heidi Taipale ◽  
Willy Gomm ◽  
Karl Broich ◽  
Wolfgang Maier ◽  
Anna-Maija Tolppanen ◽  
...  
Keyword(s):  
Health Insurance ◽  
Antiepileptic Drugs ◽  
Health Insurance Data ◽  
German Health ◽  
Dementia Risk ◽  
Insurance Data

Cancer risk from nitrosamine-contaminated valsartan

2021 ◽  
pp. dtb-2021-000041
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
Cancer Risk ◽  
Longitudinal Cohort Study ◽  
Health Insurance Data ◽  
Longitudinal Cohort ◽  
German Health ◽  
Insurance Data

AbstractOverview of: Gomm W, Röthlein C, Bowl K, et al. Valsartan contaminated with N-nitrosodimethylamine and cancer risk: a longitudinal cohort study with German health insurance data. Dtsch Arztebl Int 2021; 118:357–62. doi: 10.3238/arztebl.m2021.0129.

scholarly journals Prevalence and Therapy Rates for Stuttering, Cluttering, and Developmental Disorders of Speech and Language: Evaluation of German Health Insurance Data

2021 ◽  
Vol 15 ◽  
Author(s):  
Martin Sommer ◽  
Andrea Waltersbacher ◽  
Andreas Schlotmann ◽  
Helmut Schröder ◽  
Adam Strzelczyk
Keyword(s):  
Health Insurance ◽  
Developmental Disorders ◽  
Treatment Patterns ◽  
Newly Diagnosed ◽  
Speech And Language ◽  
Health Insurance Data ◽  
Old Patients ◽  
German Health ◽  
Insurance Data ◽  
Crude Prevalence

PurposeTo evaluate the prevalence and treatment patterns of speech and language disorders in Germany.MethodsA retrospective analysis of data collected from 32% of the German population, insured by the statutory German health insurance (AOK, Local Health Care Funds). We used The International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification (ICD-10 GM) codes for stuttering (F98.5), cluttering (F98.6), and developmental disorders of speech and language (F80) to identify prevalent and newly diagnosed cases each year. Prescription and speech therapy reimbursement data were used to evaluate treatment patterns.ResultsIn 2017, 27,977 patients of all ages were diagnosed with stuttering (21,045 males, 75% and 6,932 females, 25%). Stuttering prevalence peaks at age 5 years (boys, 0.89% and girls, 0.40%). Cluttering was diagnosed in 1,800 patients of all ages (1,287 males, 71.5% and 513 females, 28.5%). Developmental disorders of speech and language were identified in 555,774 AOK-insurants (61.2% males and 38.8% females). Treatment data indicate a substantial proportion newly diagnosed stuttering individuals receive treatment (up to 45% of 6-year-old patients), with slightly fewer than 20 sessions per year, on average. We confirmed a previous study showing increased rates of atopic disorders and neurological and psychiatric comorbidities in individuals with stuttering, cluttering, and developmental disorders of speech and language.ConclusionThis is the first nationwide study using health insurance data to analyze the prevalence and newly diagnosed cases of a speech and language disorder. Prevalence and gender ratio data were consistent with the international literature. The crude prevalence of developmental disorders of speech and language increased from 2015 to 2018, whereas the crude prevalence for stuttering remained stable. For cluttering, the numbers were too low to draw reliable conclusions. Proportional treatment allocation for stuttering peaked at 6 years of age, which is the school entrance year, and is later than the prevalence peak of stuttering.

Sign in / Sign up

Export Citation Format

Share Document